Bullish Case: Intismeran's 42% recurrence reduction (Phase 3, ESMO) plus sac-TMT's one-third mortality cut in endometrial cancer validate the post-Keytruda-cliff pipeline. Q3 beat with Keytruda $8.6B, Qlex at $830M, Winrevair +93%, raised EPS guidance to $2.77–2.82. Call volume 59% above puts, bullish risk 20% higher, and the Dec–Jan term-structure trough (~27–32 IV) invites vol-decay upside drift.

Bearish Case: MRK sits at $149.54 after a +76.7% year — much of the vaccine news is already priced (Moderna's 'muted expectations' reaction shows this). Helium's own density peaks at $142, below spot, and both Helium and market distributions skew left below $145. The 2028 Keytruda patent cliff, elevated front-week IV (46–61%), and heavy Dec put flow (135–140P) signal hedging demand and valuation risk.

Potential Outcomes:

1. 38% — Range $145–155 through December as event IV (Nov
   
   7: 46–61%) decays post-Q3/vaccine news; falsified by a break below $143.
2. 25% — Grind to $155–165 on intismeran FDA-submission momentum and Qlex conversion; watch 11/20 $155–160C flow; falsified if MRK stalls under $150.
3. 22% — Pullback to $135–145 as Helium's $142 density peak and market's left-skew imply; macro trigger via rich SPY downside vol surface.
4. 10% — Drop below $130 on pipeline/pricing shock (ADC safety, IRA); deep 12/18 $130P at 34.5 IV reflects this tail.
5. 5% — Break above $165 on M&A or surprise catalyst; 01/15 $175C at 30.6 IV is cheap lottery-ticket flow.

October 31, 2026